| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 09/13/2000 | EP1034162A1 9,10-dihydro-9,10-ethanoanthracene derivatives as phospholipase inhibitors |
| 09/13/2000 | EP1033991A1 Mometasone furoate suspensions for nebulization |
| 09/13/2000 | EP1033989A1 Method for reducing mast cell mediated allergic reactions |
| 09/13/2000 | EP1033983A1 Cyclic amino acid derivatives as cell adhesion inhibitors |
| 09/13/2000 | EP0764166B1 Corticotropin releasing factor antagonists |
| 09/13/2000 | CN1266434A 1,2,4-triazolo [4,3-B] pyrido [3,2-D] pyridazine derivatives and pharmaceutical compositions containing them |
| 09/13/2000 | CN1266431A Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists |
| 09/13/2000 | CN1265903A Traditional Chinese powder medicine for treating cough and preparation process thereof |
| 09/13/2000 | CN1265897A Capsule for heart clearing, lung moistening and asthma relieving |
| 09/13/2000 | CN1265890A Anti-anaphylaxis nose-drop |
| 09/13/2000 | CN1265887A Quick-acting asthma-relieving aerosol and its preparation method |
| 09/13/2000 | CN1056374C Tricyclic diazepine vasopression antagonists |
| 09/13/2000 | CN1056282C Lung health care drink and production process therof |
| 09/12/2000 | US6118017 Substituted-(3-cyclopentyloxy-4-methoxyphenyl)-3-phenylcyanocyclobutan-1-one |
| 09/12/2000 | US6117998 A1 adenosine receptor antagonists |
| 09/12/2000 | US6117898 Bicyclic amidine derivatives as inhibitors of nitric oxide synthetase |
| 09/12/2000 | US6117895 Dialkoxyphenyl-substituted oxazolidinones |
| 09/12/2000 | US6117886 Excellent antileukotriene activity and antihistaminic activity, and is useful for the prevention and treatment of, for example, asthma. |
| 09/12/2000 | US6117874 Benzopyran and benzo-fused compounds, their preparation and their use as leukotriene B4 (LTB4 ) antagonists |
| 09/12/2000 | US6117864 Methods employing stable preparation containing azelastine hydrochloride |
| 09/12/2000 | US6117840 Inhibits binding between vla-4 receptor expressed on inflammatory leukocytes and fibronectin cs-1 peptide expressed on endothelial cells that are involved in immunoinflammatory disease states |
| 09/12/2000 | US6117654 Nucleotide sequence coding antiinflammatroy proteins; antiarthritic agents; antiinflammatory agents; bronchodilator agents |
| 09/12/2000 | US6117447 Percutaneous absorption type preparation |
| 09/12/2000 | US6117445 Administration of an a1 adenosine receptor antagonist, or p2x purinoceptor or a compination of both offer potential as an antifibrotic or antisclerotic treatment |
| 09/12/2000 | US6116237 Methods of dry powder inhalation |
| 09/12/2000 | CA2020209C Low viscosity, highly concentrated surfactant suspension |
| 09/08/2000 | WO2000052032A1 Heterocyclic compounds, intermediates thereof and elastase inhibitors |
| 09/08/2000 | WO2000051986A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 09/08/2000 | WO2000051637A1 ANTI-TNFα ANTIBODIES IN THERAPY OF ASTHMA |
| 09/08/2000 | WO2000051605A1 Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
| 09/08/2000 | WO2000051591A1 Combinations of formoterol and mometasone furoate for asthma |
| 09/08/2000 | WO2000051578A2 Use of ceramides for the treatment of cystic fibrosis |
| 09/08/2000 | WO2000037472A3 Substituted pirroloindoles |
| 09/08/2000 | WO2000029583A3 Immunoglobulin superfamily proteins |
| 09/08/2000 | WO2000027414A3 Inhibition of the formation of vascular hyperpermeability |
| 09/08/2000 | WO2000018212A9 Platelet-derived growth factor c, dna coding therefor, and uses thereof |
| 09/08/2000 | WO2000013702A3 Use of an angiogenic factor for the treatment of microvascular angiopathies |
| 09/08/2000 | WO2000012720A3 Elongase genes and uses thereof |
| 09/08/2000 | WO2000012497B1 Quinazoline derivatives as medicaments |
| 09/08/2000 | WO2000007579A3 Use of cyclopentabenzofuran-derivatives for combating nf-$g(k)b-dependent diseases |
| 09/08/2000 | CA2365290A1 Use of ceramides for the treatment of cystic fibrosis |
| 09/08/2000 | CA2362911A1 Heterocyclic compounds, intermediates thereof and elastase inhibitors |
| 09/08/2000 | CA2330541A1 Cyclopentanone dihydropyridine compounds useful as potassium channel openers |
| 09/07/2000 | DE19909115A1 Verwendung von Ceramiden zur Behandlung cystischer Fibrose Use of ceramides in the treatment of cystic fibrosis |
| 09/06/2000 | EP1033366A2 Amide derivatives useful as Neuropeptide Y (NPY) antagonists |
| 09/06/2000 | EP1032676A2 $i(CHLAMYDIA TRACHOMATIS) GENOMIC SEQUENCE AND POLYPEPTIDES, FRAGMENTS THEREOF AND USES THEREOF, IN PARTICULAR FOR THE DIAGNOSIS, PREVENTION AND TREATMENT OF INFECTION |
| 09/06/2000 | EP1032671A1 Mammalian cytokine-like polypeptide-10 |
| 09/06/2000 | EP1032667A2 A33-related antigens and their pharmacological uses |
| 09/06/2000 | EP1032575A1 2,3-diaryl-pyrazolo(1,5-b)pyridazines derivatives, their preparation and their use as cyclooxygenase 2 (cox-2) inhibitors |
| 09/06/2000 | EP1032571A1 Piperidinylaminomethyl trifluoromethyl cyclic ether compounds as substance p antagonists |
| 09/06/2000 | EP1032569A1 Imidazole derivatives, preparation and therapeutic application thereof |
| 09/06/2000 | EP1032561A1 Substituted oximes as neurokinin antagonists |
| 09/06/2000 | EP1032423A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof |
| 09/06/2000 | EP1032415A2 Composition for the treatment of allergic conditions having cysteine and serine proteinase inhibitory activity |
| 09/06/2000 | EP1032396A1 New composition of matter |
| 09/06/2000 | EP1032394A1 Use of substituted 11-phenyl-dibenzazepine compounds for the treatment or prevention of sickle cell disease, inflammatory diseases characterized by abnormal cell proliferation, diarrhea and scour |
| 09/06/2000 | EP1032393A1 QUINOLINE-CONTAINING $g(a)-KETOAMIDE CYSTEINE AND SERINE PROTEASE INHIBITORS |
| 09/06/2000 | EP0901379B1 Type-2 chemokine binding proteins and methods of use therefor |
| 09/06/2000 | EP0665844B1 Substituted benzylaminoquinuclidines as substance p antagonists |
| 09/06/2000 | CN1265675A Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265674A 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265670A Dipeptide and related compounds which inhibit leukocyte adhesion medicated by VLA-4 |
| 09/06/2000 | CN1265669A Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265668A Subtsituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265657A Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| 09/06/2000 | CN1265652A 2-acrylaminopropanamines as tachykinin receptor antagonists |
| 09/06/2000 | CN1265647A Acrylic metalloprotease inhibitor |
| 09/06/2000 | CN1265643A Anthranilic acid analogs |
| 09/06/2000 | CN1265597A Composition comprising propolis and at least an essential oil |
| 09/06/2000 | CN1265592A A pharmaceutical composition active in reducing production of MCP-1 protein |
| 09/06/2000 | CN1265591A Coumpound |
| 09/06/2000 | CN1265590A Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels |
| 09/06/2000 | CN1265586A Use of a specific antagonist of 5HTz recepotors for preparing medicine useful for treating sleep-disordered breathing |
| 09/06/2000 | CN1056079C External application plaster for preventing and curing bronchial asthma and bronchitis |
| 09/06/2000 | CN1056077C Asthma-curing plaster |
| 09/05/2000 | US6114568 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors |
| 09/05/2000 | US6114506 Composition and method for enhancing fibrinolysis |
| 09/05/2000 | US6114389 Use of a pharmaceutically acceptable oxalate derivative for the treatment of skin conditions |
| 09/05/2000 | US6114367 Such as 3-(3-cyclopentyloxy-4-methoxy)phenyl-2-isoxazoline-5-hydroxamic acid; treating sepsis, septic shock, inflammatory bowel disease, tuberculosis, graft versus host disease or cachexia associated with aids or cancer in a mammal |
| 09/05/2000 | US6114365 Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents |
| 09/05/2000 | US6114361 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| 09/05/2000 | US6114352 Quinolinone derivative and anti-allergic agent with said quinolinone derivative as the active ingredient |
| 09/05/2000 | US6114346 Treating sleep disorders using desloratadine |
| 09/05/2000 | US6114338 Heterocyclic compounds |
| 09/05/2000 | US6114333 2-Pyrimidineamine derivatives and processes for their preparation |
| 09/05/2000 | US6114328 Isoxazoline and isoxazole fibrogen receptor antagonists |
| 09/05/2000 | US6114317 Method of locking 1α-OH of vitamin D compounds in axial orientation |
| 09/05/2000 | US6114316 Combination of bisphosphonate and tetracycline |
| 09/05/2000 | US6114311 Administering an adenviral compound |
| 09/05/2000 | US6113942 Pharmaceutical composition for piperidinoalkanol compounds |
| 09/05/2000 | CA2001160C Pyridine derivatives |
| 08/31/2000 | WO2000050639A2 Gene sequence variations with utility in determining the treatment of disease |
| 08/31/2000 | WO2000050562A2 Dna encoding snorf25 receptor |
| 08/31/2000 | WO2000050455A2 Antigen to systemic lupus erythematosis and diagnostic assay |
| 08/31/2000 | WO2000050402A1 Pde iv inhibiting compounds, compositions and methods of treatment |
| 08/31/2000 | WO2000050400A1 2-aminopyridines containing fused ring substituents |
| 08/31/2000 | WO2000050062A2 Methods and compositions for altering mucus secretion |
| 08/31/2000 | WO2000050044A1 Vaccine for house dust mite allergen using naked plasmid dna |
| 08/31/2000 | WO2000050015A1 Pharmaceutical capsule compositions containing loratadine and pseudoephedrine |
| 08/31/2000 | WO2000018910A9 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof |